Citigroup’s Elevai Labs ELAB Stock Holding History

Citigroup’s Portfolio ELAB Stock Details ELAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8	Closed	-$973	–	6158
2025 Q3	$973	Buy	+8	New	+$1.28K	﹤0.01%	5631

Other funds holding ELAB

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's ELAB Position: Q4 2025 in Review

Citigroup sold out of Elevai Labs (ELAB) in Q4 2025, closing a stake of 8 shares — an estimated $973 sold.

Citigroup first reported a position in ELAB in Q3 2025 and held it in 1 quarter. The position peaked at $973 in Q3 2025. 2 funds tracked by Wall St. Rank hold ELAB as of Q4 2025.

Citigroup reported no remaining Elevai Labs position as of Q4 2025 after selling out during the quarter.
Citigroup sold 8 Elevai Labs shares in Q4 2025, an estimated $973.
Citigroup first reported a position in Elevai Labs in Q3 2025 and held it in 1 quarter.
Citigroup's Elevai Labs position peaked at $973 in Q3 2025.
2 funds tracked by Wall St. Rank held Elevai Labs as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.